Short Interest in Precision BioSciences, Inc. (NASDAQ:DTIL) Decreases By 7.1%

Precision BioSciences, Inc. (NASDAQ:DTIL) was the target of a significant decrease in short interest in July. As of July 15th, there was short interest totalling 275,800 shares, a decrease of 7.1% from the June 30th total of 296,900 shares. Currently, 7.6% of the company’s stock are sold short. Based on an average daily volume of 38,900 shares, the short-interest ratio is currently 7.1 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Precision BioSciences stock. Janus Henderson Group PLC bought a new position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 573,052 shares of the company’s stock, valued at approximately $7,739,000. Janus Henderson Group PLC owned 8.29% of Precision BioSciences as of its most recent SEC filing. Institutional investors own 37.99% of the company’s stock.

Precision BioSciences Price Performance

NASDAQ DTIL traded up $0.04 during trading hours on Thursday, hitting $9.57. 45,238 shares of the company’s stock traded hands, compared to its average volume of 85,537. The firm’s 50-day moving average is $10.70 and its 200-day moving average is $11.65. Precision BioSciences has a 52-week low of $8.25 and a 52-week high of $19.43. The company has a market capitalization of $66.32 million, a PE ratio of -1.39 and a beta of 1.74.

Precision BioSciences (NASDAQ:DTIL) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.10. The firm had revenue of $17.58 million during the quarter, compared to analysts’ expectations of $9.35 million. Precision BioSciences had a negative net margin of 48.10% and a negative return on equity of 131.69%. Equities research analysts predict that Precision BioSciences will post -2.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DTIL has been the subject of a number of research reports. Guggenheim initiated coverage on shares of Precision BioSciences in a research report on Tuesday, April 30th. They set a “buy” rating and a $19.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Precision BioSciences in a report on Thursday, May 30th.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.